Gene Expression in Biopsies of Acute Rejection and Interstitial Fibrosis/Tubular Atrophy Reveals Highly Shared Mechanisms That Correlate With Worse Long-Term Outcomes

American Journal of Transplantation

Volumn 16, Issue 7, 2016, Pages 1982-1998

  Modena, B D ^a   Kurian, S M ^a   Gaber, L W ^b   Waalen, J ^a   Su, A I ^a   Gelbart, T ^a   Mondala, T S ^a   Head, S R ^a   Papp, S ^a   Heilman, R ^c,d   Friedewald, J J ^e   Flechner, S M ^c,f   Marsh, C L ^c,g   Sung, R S ^c,h   Shidban, H ^c,i   Chan, L ^c,j   Abecassis, M M ^e   Salomon, D R ^a,c  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c Transplant Genomics Collaborative Group (TGCG)   (United States)

^d MAYO CLINIC   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g SCRIPPS CLINIC   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ ST VINCENT MEDICAL CENTER   (United States)

^j UNIVERSITY OF COLORADO   (United States)

more..

Author keywords

basic (laboratory) research science; genomics; graft survival; immunobiology; Interstitial fibrosis and tubular atrophy; kidney (allograft) function dysfunction; kidney transplantation nephrology; organ transplantation in general; rejection: T cell mediated (TCMR); translational research science

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; DACLIZUMAB; OKT 3; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; FEMALE; GENE; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HLA SYSTEM; HUMAN; HUMAN TISSUE; IFTA GENE; IMMUNE MEDIATED INJURY; INFLAMMATION; INTERSTITIAL FIBROSIS AND TUBULAR ATROPHY; KIDNEY BIOPSY; KIDNEY FIBROSIS; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL;

EID: 84976482977     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13728     Document Type: Article

References (64)

1. Mannon RB, Matas AJ, Grande J, et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: A potent predictor of allograft failure. Am J Transplant 2010; 10: 2066–2073.
2. Park WD, Griffin MD, Cornell LD, Cosio FG, Stegall MD. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010; 21: 1987–1997.
3. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464–2472.
4. Heilman RL, Smith ML, Kurian SM, et al. Transplanting kidneys from deceased donors with severe acute kidney injury. Am J Transplant 2015; 15: 2143–2151.
5. Loupy A, Vernerey D, Tinel C, et al. Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts. J Am Soc Nephrol 2015; 26: 1721–1731.
6. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378–383.
7. Hart A, Smith JM, Skeans MA, et al. Kidney. Am J Transplant 2016; 16: 11–46.
8. Joosten SA, van Kooten C, Sijpkens YW, de Fijter JW, Paul LC. The pathobiology of chronic allograft nephropathy: Immune-mediated damage and accelerated aging. Kidney Int 2004; 65: 1556–1559.
9. El Ters M, Grande JP, Keddis MT, et al. Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transplant 2013; 13: 2334–2341.
10. Nickerson PW, Rush DN. Rejection: An integrated response. Am J Transplant 2013; 13: 2239–2240.
11. Nankivell BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006; 6: 2006–2012.
12. Legendre C, Thervet E, Skhiri H, et al. Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients. Transplantation 1998; 65: 1506–1509.
13. Seron D, Moreso F. Protocol biopsies in renal transplantation: Prognostic value of structural monitoring. Kidney Int 2007; 72: 690–697.
14. Heilman RL, Devarapalli Y, Chakkera HA, et al. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. Am J Transplant 2010; 10: 563–570.
15. Rush DN, Henry SF, Jeffery JR, Schroeder TJ, Gough J. Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation 1994; 57: 208–211.
16. Einecke G, Reeve J, Sis B, et al. A molecular classifier for predicting future graft loss in late kidney transplant biopsies. J Clin Invest 2010; 120: 1862–1872.
17. Halloran PF, Pereira AB, Chang J, et al. Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: The INTERCOM study. Am J Transplant 2013; 13: 2352–2363.
18. Storey JD. A direct approach to false discovery rates. J R Stat Soc Series B Stat Methodol 2002; 64: 479–498.
19. Morgun A, Shulzhenko N, Perez-Diez A, et al. Molecular profiling improves diagnoses of rejection and infection in transplanted organs. Circ Res 2006; 98: e74–e83.
20. Sarwal M, Chua MS, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349: 125–138.
21. Saint-Mezard P, Berthier CC, Zhang H, et al. Analysis of independent microarray datasets of renal biopsies identifies a robust transcript signature of acute allograft rejection. Transpl Int 2009; 22: 293–302.
22. Hauser P, Schwarz C, Mitterbauer C, et al. Genome-wide gene-expression patterns of donor kidney biopsies distinguish primary allograft function. Lab Invest 2004; 84: 353–361.
23. Naesens M, Li L, Ying L, et al. Expression of complement components differs between kidney allografts from living and deceased donors. J Am Soc Nephrol 2009; 20: 1839–1851.
24. Famulski KS, Reeve J, de Freitas DG, Kreepala C, Chang J, Halloran PF. Kidney transplants with progressing chronic diseases express high levels of acute kidney injury transcripts. Am J Transplant 2013; 13: 634–644.
25. Flechner SM, Kurian SM, Head SR, et al. Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant 2004; 4: 1475–1489.
26. Kainz A, Mitterbauer C, Hauser P, et al. Alterations in gene expression in cadaveric vs. live donor kidneys suggest impaired tubular counterbalance of oxidative stress at implantation. Am J Transplant 2004; 4: 1595–1604.
27. Famulski KS, de Freitas DG, Kreepala C, et al. Molecular phenotypes of acute kidney injury in kidney transplants. J Am Soc Nephrol 2012; 23: 948–958.
28. Reeve J, Einecke G, Mengel M, et al. Diagnosing rejection in renal transplants: A comparison of molecular- and histopathology-based approaches. Am J Transplant 2009; 9: 1802–1810.
29. Famulski KS, Einecke G, Reeve J, et al. Changes in the transcriptome in allograft rejection: IFN-gamma-induced transcripts in mouse kidney allografts. Am J Transplant 2006; 6: 1342–1354.
30. Einecke G, Melk A, Ramassar V, et al. Expression of CTL associated transcripts precedes the development of tubulitis in T-cell mediated kidney graft rejection. Am J Transplant 2005; 5: 1827–1836.
31. Chen R, Sigdel TK, Li L, et al. Differentially expressed RNA from public microarray data identifies serum protein biomarkers for cross-organ transplant rejection and other conditions. PLoS Comput Biol 2010; 6: e1000940.
32. Khatri P, Roedder S, Kimura N, et al. A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation. J Exp Med 2013; 210: 2205–2221.
33. Freue GV, Sasaki M, Meredith A, et al. Proteomic signatures in plasma during early acute renal allograft rejection. Mol Cell Proteomics 2010; 9: 1954–1967.
34. Perco P, Pleban C, Kainz A, Lukas A, Mayer B, Oberbauer R. Gene expression and biomarkers in renal transplant ischemia reperfusion injury. Transpl Int 2007; 20: 2–11.
35. Bunnag S, Einecke G, Reeve J, et al. Molecular correlates of renal function in kidney transplant biopsies. J Am Soc Nephrol 2009; 20: 1149–1160.
36. Stein-Oakley AN, Tzanidis A, Fuller PJ, Jablonski P, Thomson NM. Expression and distribution of epidermal growth factor in acute and chronic renal allograft rejection. Kidney Int 1994; 46: 1207–1215.
37. Hu H, Aizenstein BD, Puchalski A, Burmania JA, Hamawy MM, Knechtle SJ. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant 2004; 4: 432–437.
38. Stroo I, Stokman G, Teske GJ, et al. Chemokine expression in renal ischemia/reperfusion injury is most profound during the reparative phase. Int Immunol 2010; 22: 433–442.
39. Akalin E, Hendrix RC, Polavarapu RG, et al. Gene expression analysis in human renal allograft biopsy samples using high-density oligoarray technology. Transplantation 2001; 72: 948–953.
40. Hu H, Kwun J, Aizenstein BD, Knechtle SJ. Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine. Transplantation 2009; 87: 1814–1820.
41. Jackson JA, Kim EJ, Begley B, et al. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant 2011; 11: 2228–2234.
42. Schaub S, Nickerson P, Rush D, et al. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant 2009; 9: 1347–1353.
43. Hauser IA, Spiegler S, Kiss E, et al. Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG). J Am Soc Nephrol 2005; 16: 1849–1858.
44. Carpio VN, Noronha Ide L, Martins HL, et al. Expression patterns of B cells in acute kidney transplant rejection. Exp Clin Transplant 2014; 12: 405–414.
45. Rodrigues CA, Franco MF, Cristelli MP, Pestana JOM, Tedesco-Silva HJ. Clinicopathological characteristics and effect of late acute rejection on renal transplant outcomes. Transplantation 2014; 98: 885–892.
46. Gourishankar S, Leduc R, Connett J, et al. Pathological and clinical characterization of the “troubled transplant”: Data from the DeKAF study. Am J Transplant 2010; 10: 324–330.
47. Eid L, Tuchman S, Moudgil A. Late acute rejection: Incidence, risk factors, and effect on graft survival and function. Pediatr Transplant 2014; 18: 155–162.
48. Jiang H, Pan F, Erickson LM, et al. Deletion of DOCK2, a regulator of the actin cytoskeleton in lymphocytes, suppresses cardiac allograft rejection. J Exp Med 2005; 202: 1121–1130.
49. Spivey TL, Uccellini L, Ascierto ML, et al. Gene expression profiling in acute allograft rejection: Challenging the immunologic constant of rejection hypothesis. J Transl Med 2011; 9: 174.
50. Edemir B, Kurian SM, Eisenacher M, et al. Activation of counter-regulatory mechanisms in a rat renal acute rejection model. BMC Genom 2008; 9: 71.
51. Einecke G, Broderick G, Sis B, Halloran PF. Early loss of renal transcripts in kidney allografts: Relationship to the development of histologic lesions and alloimmune effector mechanisms. Am J Transplant 2007; 7: 1121–1130.
52. Ronco P, Debiec H. Molecular pathomechanisms of membranous nephropathy: From Heymann nephritis to alloimmunization. J Am Soc Nephrol 2005; 16: 1205–1213.
53. Allen RC, Armitage RJ, Conley ME, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993; 259: 990–993.
54. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67: 2–17.
55. Kingsbury GA, Feeney LA, Nong Y, et al. Cloning, expression, and function of BLAME, a novel member of the CD2 family. J Immunol 2001; 166: 5675–5680.
56. Kimata H, Yoshida A, Ishioka C, Fujimoto M, Lindley I, Furusho K. RANTES and macrophage inflammatory protein 1 alpha selectively enhance immunoglobulin (IgE) and IgG4 production by human B cells. J Exp Med 1996; 183: 2397–2402.
57. Halloran PF, Chang J, Famulski K, et al. Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients. J Am Soc Nephrol 2015; 26: 1711–1720.
58. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: A prospective trial. Am J Transplant 2004; 4: 438–443.
59. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157–1167.
60. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. Am J Transplant 2015; 15: 2921–2930.
61. Nickeleit V, Andreoni K. The classification and treatment of antibody-mediated renal allograft injury: Where do we stand? Kidney Int 2007; 71: 7–11.
62. Nickeleit V, Mihatsch MJ. Kidney transplants, antibodies and rejection: Is C4d a magic marker? Nephrol Dial Transplant 2003; 18: 2232–2239.
63. Magil AB, Tinckam KJ. Focal peritubular capillary C4d deposition in acute rejection. Nephrol Dial Transplant 2006; 21: 1382–1388.
64. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 Annual Data Report: Kidney. Am J Transplant 2014; 14(suppl 1): 11–44.